Trial Profile

Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Muromonab CD3 (Primary) ; Aldesleukin; Sargramostim
Indications Neuroblastoma; Osteosarcoma
Focus Adverse reactions

Most Recent Events

04 Jun 2019 Results (n=9; as of Dec 2017) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
25 Jan 2019 Planned End Date changed from 1 May 2018 to 1 Dec 2019.
25 Jan 2019 Planned primary completion date changed from 1 May 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com